Abstract
Genome-wide association studies have pinpointed numerous susceptibility loci in complex diseases like chronic immune-mediated inflammatory disorders (IMIDs), yet their impact on pathomechanisms remain poorly understood. Genetic epistasis, low effect sizes, and predominance within non-coding genomic regions, remain major challenges to the functional interpretation of IMID-associated single nucleotide polymorphisms (SNPs). To address this, we present a novel systems genomics approach which models the cumulative impact of non-coding SNPs on downstream cellular signalling and gene regulatory networks (GRNs). Applying this to the prototypical chronic IMIDs of Crohn’s disease (CD) and ulcerative colitis (UC), both forms of inflammatory bowel disease (IBD), we individually analysed 2,636 patient genomes. Signals from non-coding SNPs were found to propagate towards well-established and novel CD- and UC-associated pathogenic pathways through the signalling and gene regulatory layers. The SNP-propagated GRNs stratified CD and UC patients into distinct clusters corresponding to cell type-specific gene dysregulation and therapeutic response. This approach bridges the gap between genotype and phenotype, laying the foundations for accelerating precision medicine in complex diseases.
Competing Interest Statement
JBW, TK and SRC are named inventors on a patent application on the iSNP workflow to create disease-specific networks from SNP data. JPT has received research support from AstraZeneca. JBW has received lecture fees from Falk Pharma and financial support for research from AbbVie. DM got consultancy fees from HEALX and IOTA Pharmaceuticals. NP spoke for Allergan, Bristol Myers Squibb, Falk, Ferring, Janssen, Pfizer, Tillotts, and Takeda, and as a consultant and/or an advisory board member for AbbVie, Allergan, Celgene, Bristol Myers Squibb, Ferring, and Vifor Pharma.BV has received research support from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; Speaker fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Eli Lily, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; Consultancy fees from Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Eli Lily, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris. The remaining authors declare no competing interests.
Funding Statement
DM and AB were funded by a European Research Council Starting Grant (336159). JPT is supported by the Chain Florey Clinical PhD Fellowship jointly funded by the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) and the UKRI Medical Research Council (MRC) Laboratory of Medical Sciences (LMS). DM acknowledges financial support from Imperial College London through an Imperial College Research Fellowship grant award. The work of DM, PS, MSB, LJH, SC and TK were supported by the BBSRC Gut Microbes and Health Institute Strategic Programme BB/R012490/1 and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10355. MP was supported by the UKRI Biotechnological and Biological Sciences Research Council (BBSRC) funded by Norwich Research Park Biosciences Doctoral Training Partnership (grant numbers BB/M011216/1 and BB/S50743X/1). DM, PS, TK, SRC were also supported by a BBSRC Core Strategic Programme Grant for Genomes to Food Security (BB/CSP1720/1) and its constituent work packages, BBS/E/T/000PR9819 and BBS/E/T/000PR9817. SRC, TK and DM were supported in part by the UK Biotechnology and Biological Sciences Research Council (BBSRC) under grant numbers BB/J004529/1, BB/R012490/1 and BBS/E/F000PR10355. BV is funded by the Clinical Research Fund (KOOR), University Hospitals, Leuven, Belgium and the Research Council KU Leuven. MM was founded through the UKRI BBSRC NRP DTP as a National Productivity Investment Fund CASE Award in collaboration with BenevolentAI (BB/S50743X/1) TK and SRC were also supported by the UKRI BBSRC Institute Strategic Programme Food Microbiome and Health BB/X011054/1 and its constituent project BBS/E/F/000PR13631 . NP is supported by the Wellcome Trust (WT101159), Crohn and Colitis UK, and the NIHR Imperial Biomedical Research Centre (BRC) TK and NP were supported by the NIHR Imperial Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the NIHR or the UK Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at: https://www.ibd-leuven.com/ibd-biobank. All patients included in the analysis had given written consent to participate in the Institutional Review Board approved IBD Biobank (B322201213950/S53684).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint first authors
Data Availability
The patient genomic data is available: https://www.ibd-leuven.com/ibd-biobank The code is available: https://github.com/korcsmarosgroup/iSNP The network visualizations are available: https://www.ndexbio.org/#/networkset/5618007c-5257-11ee-aa50-005056ae23aa?accesskey=3de7d45d693d83e2fd96029b0d856f27aaa6e82337193346bbfc4621a59cbd60
